ESC Congress 2026

Dallas, Texas, August 29, 2026 Vesalio announced positive results from the NATURE randomized controlled trial, evaluating the company’s enVast™...

Tenax Therapeutics, Chapel Hill, North Carolina, August 29, 2026 Tenax Therapeutics announced the presentation of additional Phase 3 LEVEL...

SOUTH SAN FRANCISCO, Calif., Aug. 29, 2026 Cytokinetics, Incorporated announced additional clinical data for aficamten from the ACACIA-HCM and...

PRINCETON, N.J., August 26, 2026 Bristol Myers Squibb presented new long-term data for Camzyos® (mavacamten) at the European Society...

PALO ALTO, Calif., August 30, 2026 BridgeBio Pharma, Inc. presented new data from the Phase 3 ATTRibute-CM study of...

Pasadena, Calif. – August 30, 2026 Arrowhead Pharmaceuticals presented detailed Phase 3 SHASTA-3 and SHASTA-4 data showing that plozasiran...

Zug, Switzerland & Boston, Mass. – August 28, 2026 CRISPR Therapeutics presented new Phase 1a durability data for CTX310,...

Dublin, Ireland & Bridgewater, N.J. – August 28, 2026 Amarin Corporation announced new post hoc findings from the landmark...

Chicago, Ill. – August 28, 2026 GE HealthCare announced three additions to its Vivid™ cardiovascular ultrasound portfolio — Vivid...

CARLSBAD, California, August 20, 2026 Ionis Pharmaceuticals, Inc. announced that new clinical data supporting its severe hypertriglyceridemia (sHTG) treatment...